Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Luveltamab Tazevibulin |
Trade Name | |
Synonyms | STRO002|STRO 002|STRO002|luvelta |
Drug Descriptions |
Luveltamab tazevibulin is an antibody-drug conjugate (ADC) that consists of an anti-FolRa human IgG1 antibody linked to the anti-tubulin agent 3-aminophenyl hemiasterlin (SC209), which potentially inhibits growth of FolRa-expressing tumors (PMID: 36459691). |
DrugClasses | FOLR1-targeted Therapy 24 |
CAS Registry Number | 2493327-62-9 |
NCIT ID | C158067 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Luveltamab Tazevibulin | Bevacizumab Luveltamab Tazevibulin | 0 | 1 |
Carboplatin + Luveltamab Tazevibulin | Carboplatin Luveltamab Tazevibulin | 0 | 0 |
Luveltamab Tazevibulin | Luveltamab Tazevibulin | 0 | 3 |
Luveltamab Tazevibulin + Pegfilgrastim | Luveltamab Tazevibulin Pegfilgrastim | 0 | 1 |